In vitro assessment of copanlisib combination with PIM or MCL1 inhibitors
| Target . | Combination partner . | Histology . | Cell line . | Median combination index . | 95% CI . |
|---|---|---|---|---|---|
| PIM1/2 | AZD1208 | MZL | ESKOL | 0.79 | 0.62-1.10 |
| PIM1/2 | AZD1208 | MZL | HAIR-M | 0.62 | 0.35-1.11 |
| PIM1/2 | AZD1208 | MZL | HC1 | 0.23 | 0.14-0.51 |
| PIM1/2 | AZD1208 | MCL | MAVER1 | 0.99 | 0.59-1.88 |
| PIM1/2 | AZD1208 | MCL | MINO | 0.60 | 0.46-0.85 |
| PIM1/2 | AZD1208 | MCL | Z138 | 0.84 | 0.56-1.23 |
| MCL1 | MIK665 | MZL | ESKOL | 1.25 | 1.13-1.58 |
| MCL1 | MIK665 | MZL | HAIR-M | 0.65 | 0.29-1.36 |
| MCL1 | MIK665 | MZL | HC1 | 0.24 | 0.18-.67 |
| MCL1 | MIK665 | MCL | MAVER1 | >3 | n.d. |
| MCL1 | MIK665 | MCL | MINO | 0.67 | 0.41-1.27 |
| MCL1 | MIK665 | MCL | Z138 | 0.9 | 0.59-1.17 |
| Target . | Combination partner . | Histology . | Cell line . | Median combination index . | 95% CI . |
|---|---|---|---|---|---|
| PIM1/2 | AZD1208 | MZL | ESKOL | 0.79 | 0.62-1.10 |
| PIM1/2 | AZD1208 | MZL | HAIR-M | 0.62 | 0.35-1.11 |
| PIM1/2 | AZD1208 | MZL | HC1 | 0.23 | 0.14-0.51 |
| PIM1/2 | AZD1208 | MCL | MAVER1 | 0.99 | 0.59-1.88 |
| PIM1/2 | AZD1208 | MCL | MINO | 0.60 | 0.46-0.85 |
| PIM1/2 | AZD1208 | MCL | Z138 | 0.84 | 0.56-1.23 |
| MCL1 | MIK665 | MZL | ESKOL | 1.25 | 1.13-1.58 |
| MCL1 | MIK665 | MZL | HAIR-M | 0.65 | 0.29-1.36 |
| MCL1 | MIK665 | MZL | HC1 | 0.24 | 0.18-.67 |
| MCL1 | MIK665 | MCL | MAVER1 | >3 | n.d. |
| MCL1 | MIK665 | MCL | MINO | 0.67 | 0.41-1.27 |
| MCL1 | MIK665 | MCL | Z138 | 0.9 | 0.59-1.17 |
Cell lines were exposed to increasing concentrations of copanlisib and/or of the other compound for 72 hours.